AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02311634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
Study NCT02311634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ES
Description: A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
Study NCT02504424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroForm Tissue Expander
Description: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
Study NCT03175822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts Training
Description: The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
Study NCT00623350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone
Description: Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
Study NCT00623350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two way audio/video telemedicine consult
Description: Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
Study NCT00543842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
Study NCT00543842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
Study NCT00543842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting Dose 50 mg By Mouth Daily Weeks 1-3
Study NCT00543842 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
Study NCT00543842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: At least 8 weeks after radiation therapy, surgical removal of rectal tumor
Study NCT02815982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOURISH-T
Description: Overweight/obesity family intervention
Study NCT02815982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Publicly available overweight/obesity materials
Study NCT02657109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy procedure
Description: physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
Study NCT02083822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: term MRI, executive EF functions testing
Description: An MRI will be realized at term born between 25 and 32 weeks GA
Study NCT03234010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21097
Description: An electronic cigarette
Study NCT03967197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: Physiologic saline spray
Study NCT03967197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Lidocaine hydrochloride 10% spray
Study NCT01359163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etynodiol diacetate
Description: tablet, 0.5 mg, single dose
Study NCT01359163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etynodiol diacetate
Description: tablet, 0.5 mg, single dose
Study NCT01196364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: water with noncalorie sweetener
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, i.v.
Description: Single i.v. administration of placebo
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (high s.c. dose)
Description: Single high s.c. dose BI 655066
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (low i.v. dose)
Description: Single low i.v. dose BI 655066
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (high medium i.v. dose)
Description: Single high medium i.v. dose BI 655066
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (very low i.v. dose)
Description: Single very low i.v. dose BI 655066
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (low s.c. dose)
Description: Single low s.c. dose BI 655066
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (high i.v. dose)
Description: Single high i.v. dose BI 655066
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, s.c.
Description: Single s.c. administration of placebo
Study NCT01577550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066 (low medium i.v. dose)
Description: Single low medium i.v. dose BI 655066
Study NCT04498117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
Study NCT04498117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks
Study NCT04498117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, every 3 weeks
Study NCT04498117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC 6 IV Day 1 x 6 cycles (every 21 days)
Study NCT04498117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 IV Day 1 x 6 cycles (every 21 days)
Study NCT04498117 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
Study NCT04498117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
Study NCT04498117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
Study NCT01356212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
Study NCT03953612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone (PREG)
Description: 2 doses of PREG (300 or 500 mg/day)
Study NCT03953612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study NCT04348695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus simvastatin
Description: Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days
Study NCT04348695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive treatment according to usual clinical practice in the participant site.
Study NCT04084457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wild Blueberry powder
Description: Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
Study NCT04084457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment matched for fibre and vitamin C
Study NCT03610152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital Policy change
Description: Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
Study NCT00860392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer (13-C(4)-BHB)
Description: A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
Study NCT03509857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BUZZY(tm)
Description: Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager).
Study NCT03509857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: No intervention
Study NCT04542057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks
Study NCT04542057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks
Study NCT00754650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in single-use vials.
Study NCT03210792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Rib Splint
Description: Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
Study NCT03210792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Rib Splint
Description: Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
Study NCT02797197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: handgrip strength test
Study NCT02797197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT04844060 — intervention group
Intervention type: OTHER
Intervention: Lumbar punction
Description: Lumbar punction
Study NCT02852577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
Study NCT02852577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
Study NCT05597319 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection, different kind of according to pathology
Study NCT01196364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity: With noncalorie sweetener or glucose
Study NCT02954289 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary intervention
Description: Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets
Study NCT01323790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 12.5 mg oral tablet once daily
Study NCT01323790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily
Study NCT01323790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to NKTR-118
Study NCT03312621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Care Transition Care Coordination
Description: These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
Study NCT00003088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: given IV
Study NCT00003088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV
Study NCT03562793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)
Description: . COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
Study NCT03857282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercises
Description: 5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
Study NCT03857282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercises
Description: 5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
Study NCT02397876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partially Hydrolyzed Whey formula
Description: Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
Study NCT02336646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic MSC
Description: Hypoxia-cultured human bone marrow derived mesenchymal stem cells
Study NCT02336646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT03924687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain
Description: The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/).
Study NCT01321827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
Study NCT01321827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
Study NCT03490578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Description: Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
Study NCT03490578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive treadmill training
Description: Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
Study NCT03564392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Based Behavioral Intervention
Description: This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
Study NCT01226394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy plus HIPEC
Description: Laparotomy + HIPEC
Study NCT02796638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation
Description: A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
Study NCT01632657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sumatriptan
Description: Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
Study NCT01632657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
Study NCT01632657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection saline 0.5ml subcutaneously in recovery
Study NCT01632657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single injection saline 0.5ml subcutaneously in recovery
Study NCT00003088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV
Study NCT01253798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group training
Description: Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
Study NCT02732132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and Midazolam
Description: This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
Study NCT02732132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Fentanyl
Description: This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.